PROGRAM DAY BY DAY

9:00 AM – 12:00 PM  NIMH Satellite Symposium: CNS and Myeloid Cell Reservoirs

Chairs:

Joseph JEYMOHAN, Division of AIDS Research, NIMH – USA

Mario STEVENSON, University of Miami – USA

09:00 – 09:15 AM

Session Goals and NIMH Research Priorities in CNS and Myeloid Reservoirs

Joseph JEYMOHAN – Division of AIDS Research, NIMH – USA

09:15 – 09:30 AM

Unexpected Outcomes in the Rebound Zone: Utilizing Correlative PET/CT and Multi-Scale Imaging to Define SIV Rebound After ART Cessation

Thomas HOPE, Northwestern University – USA

09:30 – 09:45 AM

Macrophage-tropic HIV-1 variants populate plasma viremia in chronic and acute subjects undergoing analytic treatment interruption

Viviane MACHADO, University of Miami – USA

09:45 – 10:00 AM

Evidence of HIV Persistence in Circulating Myeloid Cells:  Implications for HIV-associated Complications and Remission

Brooks MITCHELL, University of Hawaii at Manoa – USA

10:00 – 10:15 AM

Genetic and functional differences in the CNS vs systemic HIV-1 reservoirs

Maria Paz GONZALEZ PEREZ, University of Massachusetts Medical School – USA

10:15 – 10:30 AM

HIV-infected macrophages evade NK cell-mediated killing while driving inflammation

Kiera CLAYTON, Ragon Institute – USA

10:30 – 11:00 PM Break

11:00 – 11:15 AM

Targeting lncRNA SAF to induce apoptosis in HIV-1 infected macrophages

Saikat BOLIAR, Cornell University – USA

11:15 – 11:30 AM

Low-level Persistent/Latent HIV-1 Infection of Macrophages Corresponds to Decreased NF-kB Activity

Tim HANLEY, University of Utah Health Sciences Center – USA

11:30 – 11:45 AM

Effects of Blocking NOX Signaling on  HIV Persistence and HIV-associated Neurocognitive Dysfunction in a Murine HAND Model

Christina GAVEGNANO, Emory University – USA

11:45 AM- 12:00 PM

Detection and modulation of HIV reservoirs in HIV infected patients on ART

Avi NATH, NIH – USA

9:00 AM-1:30 PM  Meeting of the Martin Delaney Collaboratories Community Advisory Board

2:00-3:30 PM  NIAID Satellite Symposium : Martin Delaney Collaboratories Research Highlights (Session 1)

2:00 – 2:30 pm DARE Collaboratory

Introduction

Steven DEEKS, University of California, San Francisco – USA

Engaging CD8+ T cell responses in SIV Reservoir Reduction or Reactivation Control

Afam OKOYE, Oregon Health & Science University – USA

 

2:30-3:00 pm BEAT-HIV Collaboratory

Introduction

Luis MONTANER, The Wistar Institute – USA

Peripheral Blood SIV/HIV Originates from Infected Cells in Tissues

Leticia KURI-CERVANTES, University of Pennsylvania – USA

Contribution of Antigenic Exposure to the Persistence of HIV-Infected CD4+ T Cells In Vivo

Francesco R. SIMONETTI, Johns Hopkins University – USA

 

3:00-3:30 pm BELIEVE Collaboratory

Introduction

R. Brad JONES, Weill Cornell Medicine – USA

Combination IL-15 Therapy in a SHIV NHP Model

James B. WHITNEY, Beth Israel Deaconess Medical Center – USA

 

3:30-4:00 PM Coffee Break

4:00-05:30 PM NIAID Satellite Symposium: Martin Delaney Collaboratories Research Highlights (Session 2)

4:00-4:30 pm I4C Collaboratory

Introduction

Dan BAROUCH, Beth Israel Deaconess Medical Center – USA

Origin of Rebound Virus in Chronically SIV-Infected Monkeys Following Treatment Discontinuation

Po-Ting LIU, Beth Israel Deaconess Medical Center – USA

HIV-1 Diversity Considerations for Clinical Studies of Passively Transferred Broadly Neutralizing Antibodies

Kshitij WAGH, Los Alamos National Laboratory – USA

 

4:30-5:00 pm defeatHIV Collaboratory

Introduction

Hans-Peter KIEM, Fred Hutchinson Cancer Research Center – USA

CAR T Cell-Treated Rhesus Macaques Suppress SHIV Viremia Following ART Treatment Interruption

Christopher PETERSON, Fred Hutchinson Cancer Research Center – USA

 

5:00-5:30 pm CARE Collaboratory

Introduction

David MARGOLIS, University of North Carolina at Chapel Hill – USA

Novel Bivalent Chemical Degraders to Reverse HIV Latency

Anne-Marie TURNER,  PhD, UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 – USA

Improved Killing of HIV-infected Cells by a Combination of Three Antibodies: Implications for Clearing Persistent Infection

Marina TUYISHIME, PhD, Department of Surgery, Duke University Medical Center, Durham, NC – USA

 

5:30-05:45 CanCURE Overview

Eric COHEN, IRCM, Human Retrovirology research unit, Montréal – CAN

5:45-06:00 PM Break

6:00 WELCOME

  • Alain LAFEUILLADE, Infectious disease private practice, La Valette du Var, FRA

6:05-7:30 PM Opening Lecture
Introduction

Chairs:

Karl SALZWEDEL, National Institute of Allergy and Infectious Diseases, Bethesda, USA

Alain LAFEUILLADE, Infectious disease private practice, La Valette du Var – FRA

  • Ending the HIV Pandemic: Follow the ScienceAnthony S. FAUCI, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, WA – USA
  • Bringing curative interventions for HIV to resource-limited parts of the world – Mike McCUNE, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation – USA

07:30 Welcome dinner

8:00-10:00 AM – SESSION 1: BASIC SCIENCE OF HIV LATENCY

Chairs:

Una O’DOHERTY,Associate Professor Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA – USA

Jonathan KARN, Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine, Director, Case Center for AIDS Research, Cleveland/Akron, OH – USA

Christina PSOMAS, Clinical and Translational Research in the Department of Infectious Diseases of Montpellier University Hospital – FRA

 

OP 1.0 Cellular Mechanisms that Establish and Maintain HIV Latency

Andrew HENDERSON, Professor of Medicine, Assistant Dean Graduate Medical Sciences Department of Medicine and Microbiology, Section of Infectious Diseases Boston University School of Medicine, Boston, MA – USA

OP 1.1: Expression Profiling of HIV Latently-Infected Cells Using Nanostring And Mass Cytometry
Author(s): H. Sperber 1, 2,*, T. Ma 3, N.R. Roan 3, S.K. Pillai 1
1 Vitalant Research Institute – San Francisco (USA)
2 Free University of Berlin – Berlin (GER)
3 Gladstone Institutes – San Francisco (USA)

OP 1.2: A quantitative single cell, single molecule RNA-FISH+IF and single cell RNA-seq
analysis reveals stochasticity of reactivation of latent provirus
Author(s): G. Kalpana 1,* , R. Pathak 1, A. La Porte 1, E. Bock 1, C. Eliscovich 1, L. Martins 2, A. Spivac 2, U. Dixit 1, V. Planelles 2, R. Singer 1
1 Albert Einstein College of Medicine – New York (USA)
2 University of Utah School of Medicine – Salt Lake City (USA)
„

OP 1.3 : Single-cell transcriptome sequencing of latently-infected cells ex vivo using PCRactivated cell sorting (PACS)
Author(s): I. Clark 1, 2,*, A. Abate 1, F. Quintana 2, S. Deeks 1, D. Douek 3, E. Boritz 3,*
1 UCSF – San Francisco (USA)
2 Harvard – Boston (USA)
3 NIH – Bethesda (USA)

OP 1.4 : Single cell analysis of in vivo HIV reservoir uncovers novel markers of latent cells
Author(s): N. Roan 1,*, Jason Neidleman 1, 8, Xiaoyu Luo1, Julie Frouard1, 8, Feng Hsiao 1, 8, Guorui Xie 1, 8, Vincent Morcilla 2, Katherine Sholtis James 3, Rebecca Hoh 4, Ma Somsouk 5, Peter Hunt 6, Steve Deeks 4, Nancie Archin 3, Sarah Palmer 2, Warner C. Greene 1,7
1 Gladstone Institute of Virology and Immunology, San Francisco, CA (USA)
2 Centre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW 2145 (AUS)
3 Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (USA)
4 Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, CA (USA)
5 Department of Medicine, Division of Gastroenterology, San Francisco General Hospital and University of California, San Francisco, CA (USA)
6 Division of Experimental Medicine, University of California San Francisco, San Francisco, CA (USA)
7 Department of Medicine, University of California, San Francisco, CA (USA)
8 Department of Urology, University of California, San Francisco, CA (USA)

OP 1.5 : Quantifying the contribution of cellular proliferation to maintaining the HIV reservoir
Author(s): A. Hill 1,*, G. Andrei 1, J. Gerold 1
Harvard University – Cambridge, Ma (USA)

OP 1.6 : Tyrosine Kinase Inhibition: the new Front in HIV Cure Efforts
Author(s): V. Planelles 1,*, M. Szaniawski 1, E. Williams 1, E. Innis 1, L. Martins 1, A. Spivak 1, J. Alcami 2, M. Coiras 2
1 University of Utah – Salt Lake City (USA)
2 Instituto de Salud Carlos III, Madrid Spain – Madrid (SPA)

10 :00-10 :30 AM Coffee Break

10:30-12:30 PM – SESSION 2: IN VITRO AND ANIMAL MODEL STUDIES OF HIV PERSISTENCE

Chairs:

Ann CHAHROUDI, Associate Professor Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA – USA

Afam OKOYE, Research Associate Professor Vaccine & Gene Therapy Institute, and Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton – USA

OP 2.0 In vivo platforms for the evaluation of novel approaches to HIV persistence and eradication

J. Victor GARCIA MARTINEZ, Professor of Medicine, Center for AIDS Research, Division of Infectious Diseases, Chapel Hill – USA

 

OP 2.1 Understanding the establishment and persistence of the rebound competent reservoir using barcoded viruses

Brandon F. KEELE, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick – USA

 

„ OP 2.2 : Barcoded viruses facilitate tracking changes to the composition of the rebound-competent reservoir
Author(s): T. Immonen 1,*, C. Fennessey 1, J. Lifson 1, B. Keele 1,*
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research – Frederick (USA)

 

„ OP 2.3 : Delay in Viral Rebound with TLR7 Agonist, N6-LS and PGT121 in SHIV-infected
Macaques
Author(s): D. Hsu 1,*, D. Silsorn 2, R. Imerbsin 2, A. Pegu 3, J. Mascola 3, R. Geleziunas 4, R. Koup 3,
D. Barouch 5, N. Michael 6, S. Vasan 6
1 MHRP – Bangkok (THA)
2 AFRIMS – Bangkok (THA)
3 NIH – Bethesda (USA)
4 Gilead Sciences – Foster City (USA)
5 BIDMC – Boston (USA)
6 MHRP – Silver Spring (USA)
„

OP 2.4 : Chimeric Antigen Receptor T-Cells and Stem Cells Control and Protect Against SHIV Replication in Nonhuman Primates
Author(s): C. Peterson 1,*, B. Rust 1, A. Zhen 2, K. Brandenstein 1, N. Poole 1, C. Maldini 3, G. Ellis 3, S. Kitchen 2, J. Riley 3, H.P. Kiem 1
1 Fred Hutchinson Cancer Research Center – Seattle (USA)
2 University of California, Los Angeles – Los Angeles (USA)
3 University of Pennsylvania – Philadelphia (USA)
„

OP 2.5 : The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIVinfected rhesus macaques is potentiated by CD8a cell depletion
Author(s): M. Mavigner 1,*, A. Brooks 1, C. Mattingly 1, T. Vanderford 1, B. Keele 2, J. Lifson 2, R. Dunham 3, D. Margolis 3, G. Silvestri 1, A. Chahroudi 1
1 Emory University – Atlanta (USA)
2 Frederick National Laboratory for Cancer Research – Frederick (USA)
3 UNC Chapel Hill – Chapel Hill (USA)
„

OP 2.6 : Utilizing correlative PET/CT and multiscale imaging to define the dynamics of SIV infected cells from early ART initiation to the rebound after analytic treatment interruption
Author(s): T. Hope 1,*, M.S. Arif 1, Y. Thomas 1, I. Clerc 1, A. Carias 1, E. Allen 1, M. Mcraven 1, M. Ramirez 2, P. Santangelo 3, F. Villinger 2
1 Northwestern – Chicago (USA)
2 New Iberia Research Center – New Iberia (USA)
3 Georgia Tech – Atlanta (USA)

12:30-2:00 PM Lunch

2:00 – 4:00 PM – SESSION 3: VIROLOGY OF HIV PERSISTENCE

Chairs :

Katherine BAR, Associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, Pensylvania – USA

Zabrina BRUMME, Director, Laboratory Program, BC Centre for Excellence in HIV/AIDS, Saint Paul Hospital, Vancouver – CAN

OP 3.0 CD4-MBL-CAR/CXCR5 T cell immunotherapy shows promise at reducing SIV replication post-ART release

Pamela SKINNER, Professor Department of Veterinary and Biomedical Sciences Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program, University of Minnesota, MN – USA

 

OP 3.1: Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
Author(s): M. Peluso 1,*, P. Bacchetti 1, K. Ritter 2, S. Beg 3, P. Hunt 1, T. Henrich 1, J. Siliciano 3, R. Siliciano 3, G. Laird 2, S. Deeks 1
1 University of California, San Francisco – San Francisco (USA)
2 Accelevir Diagnostics – Baltimore (USA)
3 Johns Hopkins School of Medicine – Baltimore (USA)
„

OP 3.2: Women undergoing reproductive aging show increased reservoir sizes associated
with removal of hormonal control of HIV-1 latency by estrogen
Author(s): J. Karn 1,*, C. Dobrowolski 1,*, E. Scully 2, K.M. Weber 3, A.L. Landay 4
1 Department of Molecular Biology and Microbiology, Case Western Reserve University
School of Medicine – Cleveland (USA)
2 Johns Hopkins University, Department of Medicine, Division of Infectious Diseases – Baltimore (USA)
3 WIHS/CORE Center of Cook County Health – Chicago (USA)
4 Rush University Medical Center, Department Internal Medicine – Chicago (USA)
„

OP 3.3: Contribution of Antigenic Exposure to the Persistence of HIV-infected CD4+
T-cells in vivo
Author(s): F. Simonetti 1,*, H. Zhang 1, G. Soroosh 1, S. Beg 1, H. Raymond 2, K. Mccormick 2, S. Deeks 3, F. Bushman 2, J. Siliciano 4, R. Siliciano 1
1 Johns Hopkins University – Baltimore (USA)
2 University of Pennsylvania – Philadelphia (USA)
3 University of California San Francisco – San Francisco (USA)
4 Johns Hoppkins University – Baltimore (USA)
„

OP 3.4: Multiplexed RNA flow cytometric FISH allows single-cell viral transcriptional
profiling and phenotypic characterization of translation-incompetent HIV reservoirs
Author(s): D. Kaufmann 1,*, M. Dubé 1,*, G. Sannier 1, N. Brassard 1, G.G. Delgado 1, A. Baxter 1, J.P. Routy 2, N. Chomont 1
1 Research Centre of the Centre Hospitalier de l’Université de Montréal (CRCHUM) and Université de Montréal, Montreal, Quebec, Canada – Montréal (CAN)
2 Chronic Viral Illnesses Service and Division of Hematology, McGill University Health Centre – Montréal (CAN)
„

OP 3.5: Low Viral Reservoir Treated Individuals Show Unusual HIV Latency Distribution
Author(s): C. Gálvez 1,*, V. Urrea 1, S. Benet 1, B. Mothe 1, L. Bailón 2, J. Dalmau 1, L. Leal 3, F. García 3, J. Martinez-Picado 1, M. Salgado 1
1 AIDS Research Institute IrsiCaixa – Badalona (SPA)
2 Infectious Diseases Department, University Hospital “Germans Trias i Pujol” – Badalona (SPA)
3 Infectious Diseases Department, Hospital Clínic, University of Barcelona – Barcelona (SPA)

4:00 -7.00 PM – POSTER VIEWING SESSION WITH WINE AND CHEESE TASTING

7 :00 PM Free dinner

8:00-10:00 AM – SESSION 4: IMMUNOLOGY OF HIV PERSISTENCE

Chairs:

Lydie TRAUTMANN, Associate Professor, OHSU, Vaccine & Gene Therapy Institute, Beaverton – USA

Brad JONES,Assistant Professor, Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Columbia, WA – USA

 

OP 4.0 T Cells and The Cure Agenda

Bruce WALKER, Founding Director of the Ragon Institute of MGH, MIT and Harvard and the Director of the Harvard University Center for AIDS Research, Cambridge, MA – USA

 

OP 4.1 HIV persistence during ART: Keeping memory, keeping HIV

Nicolas CHOMONT, Associate Professor in the Department of Microbiology and Immunology at the Université de Montréal – CHUM Research Center, Montreal – CAN

 

OP 4.2 : Characterizing “exceptional” control among HIV elite controllers
Author(s): M. Peluso 1,*, P. Burbelo 2, S. Kumar 1, S. Munter 1, R. Hoh 1, S. Lee 1, P. Hunt 1, R. Rutishauser 1, T. Henrich 1, S. Deeks 1
1 University of California, San Francisco – San Francisco (USA)
2 National Institutes of Health – Bethesda (USA)
„

OP 4.3 : Single-cell TCR sequencing reveals that clonally expanded cells highly contribute
to the inducible HIV reservoir during ART
Author(s): P. Gantner 1,*, A. Pagliuzza 2, M. Pardons 1, M. Ramgopal 3, J.P. Routy 3, R. Fromentin 2, N. Chomont 1
1 Université de Montréal – Montréal (CAN)
2 CRCHUM – Montréal (CAN), 3Midway Immunology & Research Center – Fort Pierce (USA)
„

OP 4.4 : Single-cell phenotyping of HIV-infected expanded clones in ART-suppressed individuals
Author(s): C. Dufour 1,*, M. Pardons 1, R. Fromentin 1, M. Massanella 1, S. Palmer 2, S. Deeks 3, B. Murrell 4, J.P. Routy 5, N. Chomont 1
1 Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal – Montreal (CAN)
2 Centre for Virus Research, The Westmead Institute of Medical Research, The University of Sydney – Sydney (AUS)
3 Department of Medicine, University of California San Francisco – California (USA)
4 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet – Stockholm (SWE)
5 Division of Hematology & Chronic Viral Illness Service, McGill University Heath Centre – Montreal (CAN)
„

OP 4.5 : The IciStem consortium: T-cell immunology in HIV-1 infected individuals after
allogeneic stem cell transplantation
Author(s): J. Martinez-Picado 3,*, J. Eberhard 1,*, M. Angin 2, C. Passaes 2, M. Salgado 3, J.L. Díez Martín 4, M. Nijhuis 5, A. Wensing 5, , J. Schulze Zur Wiesch 1, A. Sáez-Cirión 2
1 Department of Medicine, Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf – Hamburg (GER)
2 Institut Pasteur, HIV, Inflammation and Persistence – Paris (FRA)
3 AIDS Research Institute IrsiCaixa – Barcelona (SPA)
4 Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitarias Gregorio
Marañón, Universidad Complutense – Madrid (SPA)
5 University Medical Center – Utrecht (NET)

„OP 4.6 : Dynamics of HIV-Specific T-Cells on Long-Term ART Differ by Antigen Recognized and by Sex
Author(s): Eva M. Stevenson1, Adam R. Ward 1,2,3, Thomas R. Dilling 1, John K. Bui 1, John Mellors 4, Rajesh Gandhi 5, Deborah McMahon 4, Joseph Eron 6, Ronald Bosch 7, Christina Lalama 7, Joshua Cyktor 4, and Brad Jones 1,2, for the A5321 Team
1 Division of Infectious Diseases, Weill Cornell Medicine, New York, NY (USA)
2 Department of Microbiology, Immunology, and Tropical Medicine, George Washington
University, Washington, DC (USA)
3 PhD program in Epidemiology, George Washington University, Washington, DC (USA)
4 University of Pittsburgh, Pittsburgh, PA (USA)
5 Massachusetts General Hospital, Boston, MA (USA)
6 University of North Carolina, Chapel Hill, NC (USA)
7 Harvard University, Boston, MA (USA)

10 :00-10 :30 AM Coffee Break

10:30-12:30 PM – SESSION 5: HUMAN STUDIES AND DRUG DEVELOPMENT I

Chairs:

Bonnie HOWELL, Executive Director, Infectious Disease and Vaccines Merck, West Point, Pennsylvania, PE – USA

Javier MARTINEZ PICADO, ICREA Research Professor at Institut de Recerca de la Sida – IrsiCaixa, Barcelona – SPA

 

OP5.0 Discovery and development of novel latency reversing agents

Richard DUNHAM, Scientific Leader and Fellow at ViiV Healthcare; Adj Asst Professor at UNC-CH Région de Raleigh-Durham, NC – USA

 

OP 5.1 Virologic Outcomes of Vesatolimod Administration in People Living with HIV on ART

Joseph HESSELGESSER, Research scientist, Gilead, Foster city, CA – USA

 

OP 5.2 : HIV Post-Treatment Control Despite Plasma Viral Evolution and Dual Infection
Author(s): J. Li 1*, B. Etemad 1, G. Namazi 1, Y. Wen 2, N. Jilg 3, E. Esmaeilzadeh 1, X. Zhang 4, R. Sharaf 1, Z. Brumme 5, M. Kearney 6,
1 Brigham and Women’s Hospital, Harvard Medical School – Boston (USA)
2 China Medical University – Shenyang (CHI)
3 Massachusetts General Hospital, Harvard Medical School – Boston (USA)
4 Beijing Friendship Hospital – Beijing (CHI)
5Simon Fraser University – Burnaby (CAN), 6Frederick National Laboratory for Cancer Research – Frederick (USA)

„ OP 5.3 : Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
Author(s): L. Pache 1,*, P. Teriete 1, M.D. Marsden 2, A.M. Spivak 3, D. Heimann 1, A.J. Portillo 1, V. Planelles 3, J.A. Zack 2, N.D.P. Cosford 1, S.K. Chanda 1
1 Sanford Burnham Prebys Medical Discovery Institute – La Jolla (USA)
2 University of California, Los Angeles – Los Angeles (USA)
3 University of Utah School of Medicine – Salt Lake City (USA)

OP 5.4 : HIV Particles Expressed in Semen under INSTI-based Suppressive Therapy are
Largely Myeloid Cell-Derived and Exhibit Widely Diverse Genotypes
Author(s): J. Johnson 1,*, D. Anderson 2, J.F. Li 1, A. Santos Tino 3, J. Politch 2, J. Lipscomb 1, J. Defelice 4, M. Gelman 4, K. Mayer 4
1 CDC, Atlanta (USA)
2 BU School of Medicine, Boston (USA)
3 The DESA Group, Atlanta, USA 4The Fenway Institute,Boston (USA)

OP 5.5 : Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study
Author(s): Thomas A Rasmussen1, Laskhmi Rajdev2, Ajantha Rhodes1, Ashanti Dantanarayana1, Surekha Tennakoon1, Socheata Chea1, Danielle Rigau3, Shelly Lensing4, Rachel Rutishauser5, Sonia Bakkour6, Michael Busch6, Dirk P Dittmer7, Steven Deeks5, Christine Durand3, Sharon R Lewin1, 8
1 The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, (AUS)
2 Department of Medicine, Albert Einstein College of Medicine, New York (USA)
3 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (USA)
4 Department of Biostatistics, University of Arkansas for Medical Biosciences, Arkansas (USA)
5 Department of Medicine, University of California San Francisco, California (USA)
6 Vitalant Research Institute, San Francisco, California (USA)
7 Department of Microbiology and Immunology, University of North Carolina (USA)
8 Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne (AUS)

OP 5.6 : Intact Proviral DNA Levels Decline in People with HIV on Antiretroviral Therapy (ART)
Author(s): J. Cyktor 2,*, R. Gandhi 1,*, R. Bosch 3, H. Mar 3, G. Laird 4, B. Macatangay 2, J. Eron 5, R. Siliciano 6, D. Mcmahon2, J. Mellors2
1 Massachusetts General Hospital – Boston (USA),
2 University of Pittsburgh – Pittsburgh (USA),
3 Harvard TH Chan School of Public Health – Boston (USA),
4 Accelevir Diagnostics – Baltimore (USA),

12:30-2:00 PM Lunch

2:00 – 4:00 PM – SESSION 6: NEW THERAPEUTIC APPROACHES I

Chairs:

Ya-Chi HO, Assistant Professor of Microbial Pathogenesis and Medicine; Investigator, HIV Reservoirs and Viral Eradication Transformative Science Group (Cure TSG) New Haven, CT – USA

Alberto BOSQUE, Assistant Professor,Department of Microbioloy, Immunology and Tropical Medicine, George Washington Universisty, Washington, WA – USA

 

OP 6.0 Genome editing against HIV

Paula CANNON, Professor of Molecular Microbiology & Immunology; Associate Director
of Cross School Programs for the MESH Academy Molecular Microbiology and Immunology, Los Angeles, CA – USA

 

OP 6.1: Multispecific anti-HIV duoCAR-T cell therapy mediates robust HIV suppression and elimination of HIV-infected cells in humanized mice
Author(s): K. Anthony-Gonda 1,*, A. Bardhi 2, A. Ray 2, W. Krueger 1, D. Schneider 1, Z. Zhu 1, R. Orentas 1, D. Dimitrov 3, H. Goldstein 2, B. Dropulic 1
1 Lentigen, a Miltenyi Biotec Company – Gaithersburg (USA)
2 Albert Einstein College of Medicine – Bronx (USA)
3 University of Pittsburg – Pittsburg (USA)

 

OP 6.2: Location, abundance and persistence of CAR/CXCR5 transduced T cells within
lymphoid tissues of SIV-infected rhesus macaques
Author(s): H. Abdelaal 1,*, M. Pampusch 1, P. Skinner 1, E. Berger 2
1 University of Minnesota – Minneapolis (USA)
2 University of Minnesota – The National Institutes of Health, Bethesda, Md (USA)
„

OP 6.3: Combinatorial latency reversal activity of Inhibitor of Apoptosis antagonists (IAPa) with mechanistically distinct classes of HIV latency reversal agents
Author(s): Shane D. Falcinelli1,3, David M. Irlbeck1,5, Anne-Marie Turner1, Jackson Peterson1,3, Frances Potjewyd2, Lindsey I. James1,2, David M. Margolis1,3,4, Nancie M. Archin1,4, Richard M. Dunham1,5
1 UNC HIV Cure Center (USA)
2 Center for Integrative Chemical Biology and Drug Discovery (USA)
3 Dept. of Microbiology and Immunology (USA)4Dept. of Medicine University of North Carolina, Chapel Hill, NC (USA)
5 HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC (USA)
„

OP 6.4: α4α7-blockade delays viral rebound in SHIV infected macaques treated with a
combination of HIV bNAbs
Author(s): E. Martinelli 1,*
CBR, Population Council – New York (USA)
„

OP 6.5: Replacing daily cART with AAV-expressed eCD4-Ig
Author(s): M. Gardner 1,*, M. Davis-Gardner 1, M. Farzan 1
1 The Scripps Research Institute – Jupiter (USA)

4:00 -7.00 PM – POSTER SESSION // POSTER VIEWING with wine and cheese tasting

7:00 PM Free evening

8:00-10:00 AM – SESSION 7: HUMAN STUDIES AND DRUG DEVELOPMENT II

Chairs:

David SMITH, University of California, San Diego School of Medicine, La Jolla- USA

Javier MARTINEZ PICADO, ICREA Research Professor at Institut de Recerca de la Sida – IrsiCaixa, Barcelona – SPA

 

OP 7.0 Main challenges of human studies in the HIV eradication field

Beatriz MOTHE PUJADAS, MD, PhD. Associate Investigator. HIV Unit & IrsiCaixa AIDS Research Institute. Hospital Germans Trias i Pujol. UVic-UC, Barcelona – SPA

 

OP 7.1 Whole Body Imaging of HIV Persistence, Viral Biomarkers and Immune Activation

Timothy HENRICH, Associate Professor of Medicine at University of California, San Francisco, CA – USA

 

OP 7.2: Plasma and Antibody Glycomic Biomarkers of Time to HIV Rebound and Viral Setpoint
Author(s): L. Giron 1,*, E. Papasavvas 1, L. Azzoni 1, K. Mounzer 2, J. Kostman 2, I. Sanne 3, C. Firnhaber 4, Q. Liu 1, L. Montaner 1, M. Abdel-Mohsen 1,*
1 The Wistar Institute – Philadelphia (USA)
2 Philadelphia FIGHT – Philadelphia (USA)
3 University of the Witwatersrand – Johannesburg (ZAF)
4 University of Colorado School of Medicine – Aurora (USA)

OP7.3: Single cell RNA-seq identifies host genes that correlate with HIV-1 reservoir size
Author(s): R. Thomas 1,*, A. Waickman 2, P. Ehrenberg 1, A. Geretz 1, M. Eller 1, S. Tovanabutra 1, J. Ananworanich 1, N. Chomont 3, J. Currier 2, N. Michael 1
1 U.S. Military HIV Research Program, Walter Reed Army Institute of Research – Silver Spring (USA)
2 Viral Diseases Branch, Walter Reed Army Institute of Research – Silver Spring (USA)
3 Université de Montréal, Faculty of Medicine – Montreal (CAN)
„

OP 7.4: Sex differences in the latent reservoir of virally suppressed HIV-1 infected individuals living in Rakai, Uganda
Author(s): T.C. Quinn 3,*, J. Prodger 1,*, A.M. Capoferri 2, K. Yu 1, S.J. Reynolds 3, J. Kasule 4, D. Serwadda 4, E. Scully 2, K.J. Kwon 2, A.D. Redd 3
1 Western University – London (CAN)
2 Johns Hopkins School of Medicine – Baltimore (USA)3National Institutes of Health – Baltimore (USA)
4 Rakai Health Sciences Program – Kalisizo (UGA)
„

OP 7.5: Clones Of HIV Infected Cells Are Widely Distributed In T Cell Subsets In Blood
And In Anatomic Tissues
Author(s): F. Maldarelli 1,*, M. Gozoulis 1, X. Wu 2, L. Perez 3, R. Gorelick 4, C. Lange 1, S. Hill 1, J. Virga1, T. Uldrick 5, R. Yarchoan 6, S. Hughes 1
1 CCR/NCI – Frederick (USA)
2 Leidos Inc – Peoria (USA)
3 VRC/NIAID – Bethesda (USA)
4 Leidos, INC – Peoria (USA)
5 CCR/NCI – U Washington (USA)
6 CCR/NCI – Bethesda (USA)

OP 7.6: Tissue-specific differences in the mechanisms that govern HIV latency in blood,
liver, gut and genital tract in ART-suppressed women
Author(s): S. Moron-Lopez 1,*, G. Xie 2, P. Kim 3, J. Wong 1, J. Price 4, N. Elnachef 4, R. Greenblatt 4, P. Tien 1, N. Roan 2, S. Yukl 1
1 University of California San Francisco – SFVAMC – San Francisco (USA)
2 University of California San Francisco – Gladstone Institutes – San Francisco (USA)
3 San Francisco VA Medical Center (SFVAMC) – San Francisco (USA)
4 University of California San Francisco – San Francisco (USA)

10:00-10:30 AM Coffee Break

10:30-12:30 PM – SESSION 8: NEW THERAPEUTIC APPROACHES II

Chairs:

Susanna VALENTE, Associate Professor Department of Immunology and Microbiology130 Scripps Way, 3C1, Jupiter, FL – USA

Lesley de ARMAS, Academic research scientits at the University of Miami, Miller School of Medecine, Miami – USA

Poli GUIDO, Salute San Raffaele University School of Medicine & Head AIDS
Milan – ITA

 

OP 8.0 A viable pathway to HIV-1 remission

Michael FARZAN, Professor an d co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute, FL – USA

 

 

OP 8.1: The Human IL-15 Superagonist N803 Does Not Reverse Latency in ART-suppressed, SHIV-infected macaques
Author(s): G. Webb 1,*, J. Berrocal 2, K. Busman-Sahay 1, S. Abdulhaqq 1, J. Smedley 1, J. Safrit 3, J. Estes 1, P. Skinner 2, J. Sacha 1
1 Oregon Health and Science University – Portland (USA)
2 University of Minnesota – St. Paul (USA)
3 NantKWest – Culver City (USA)

„OP 8.2: How Long is Long-term? Delivery of anti-HIV Antibodies Using AAV Vector
Author(s): J. Martinez-Navio 1,*, S. Fuchs 1, D. Mendes 1, E. Rakasz 2, G. Gao 3, J. Lifson 4, R. Desrosiers 1,*
1 University of Miami – Miami (USA)
2 Wisconsin National Primate Research Center UW – Madison (USA)
3 Gene Therapy Center UMass – Worcester (USA)
4 Frederick National Laboratory for Cancer Research – Frederick (USA)
„

OP 8.3: Intensification of ART with ABX464 decreases the total HIV reservoir and HIV
transcription initiation in CD4+ T cells from HIV-infected ART-suppressed individuals
Author(s): S. Bernal 1,*, S. Moron-Lopez 2,*, J.M. Steens 3, J.K. Wong 4, J. Martinez-Picado 1, S.A. Yukl 4
1 IrsiCaixa AIDS Research Institute – Badalona (SPA)
2 University of California San Francisco – San Francisco (USA)
3 ABIVAX – Paris (FRA)
4 San Francisco VA Medical Center – San Francisco (USA)
„

OP 8.4: HIV persistence despite reservoir decay during combinatorial immunotherapy
including therapeutic conserved elements (CE) DNA vaccination, αPD-1 therapy, GS-986 TLR7- agonism, and CCR5 gene-edited CD4+ T cell infusion in rhesus macaques
Author(s): S. Dross 1,*, C. Peterson 2, M. O’ Connor 1, H. Tunggal 1, J. Li 1, K. Jerome 2, H.P. Kiem 2, B. Felber 3, J. Mullins 1, D. Fuller 1
1 Department of Microbiology, University of Washington – Seattle (USA)
2 Fred Hutchinson Cancer Research Center – Seattle (USA)
3 Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute – Frederick (USA)
„

OP 8.5: PD-1 Blockade boost Vaccine-Induced anti-HIV responses in the absence of HIV reactivation
Author(s): M. Marin Lopez 1,*, J. G Prado 1,* E. Jimenez-Moyano 1, D. Ouchi 1, O. Blanch-Lombarte 1, D. Gorman 2, T. Hanke 3, C. Brander 1, B. Howell 4, B. Mothe 1
1 IrisiCaixa – Badalona (Barcelona) (SPA)
2 Merck & Co. Inc. – Palo Alto, California (USA)
3 The Jenner Institute Nuffield Department of Medicine, University of Oxford – Oxford (GBR),
4 Department of Infectious Disease, Merck & Co. Inc. – Kenilworth, Nj (USA)
„

OP 8.6: Post-therapy viral set-point abatement following combined antiproliferative and
immune-boosting interventions: Results: from a randomized clinical trial
Author(s): R. Sobhie Diaz 1,*, L.B. Giron 2, J. Galinskas 1, J. Hunter 1, M. Janini 1, I.L. Shytaj 3, R. Cauda 4, M.C. Sucupira 5, J. Maricato 5, A. Savarino 6
1 Federal University of Sao Paulo, Infectious Diseases Department – São Paulo (BRA)
2 Wistar Institute – Philadelphia (USA)
3 Heidelberg University Hospital, Department of Infectious Diseases – Heidelberg (USA)
4 Institute of Infectious Diseases, Gemelli Hospital, Catholic University of Sacred Heart – Rome (ITA)
5 Federal University of Sao Paulo, Infectious Diseases Department – São Paulo (BRA)
6 Department of Infectious Diseases, Italian Institute of Health – Rome (ITA)
„

OP 8.7: B cell depletion alone or in combination with IL-15 or PD-1 blockade facilitates
enhanced control of virus replication in SIV-infected rhesus macaques
Author(s): Y. Fukazawa 1,*, L.J. Picker 1,* , H. Behrns 1, B.E. Randall 1, B. Varco-Merth 1, H. Park 1, B.K. Felber 2, G.N. Pavlakis 2, J.D. Lifson 3, A.A. Okoye 1
1 Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University – Beaverton, Or (USA)
2 Center for Cancer Research, National Cancer Institute – Frederick, Md (USA)

12:30 PM Closing ceremony